UY31558A1 - Nueva forma cristalina del acido (2r)-(3-amino-2-fluoropropil) fosfinico - Google Patents

Nueva forma cristalina del acido (2r)-(3-amino-2-fluoropropil) fosfinico

Info

Publication number
UY31558A1
UY31558A1 UY31558A UY31558A UY31558A1 UY 31558 A1 UY31558 A1 UY 31558A1 UY 31558 A UY31558 A UY 31558A UY 31558 A UY31558 A UY 31558A UY 31558 A1 UY31558 A1 UY 31558A1
Authority
UY
Uruguay
Prior art keywords
amino
acid
fluoropropil
phosphinic
crystal form
Prior art date
Application number
UY31558A
Other languages
English (en)
Inventor
Erica Tjerneld
Jeroen Koningen
Ida Hiyer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40801457&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31558(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UY31558A1 publication Critical patent/UY31558A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a una nueva forma cristalina del ácido (2R)-(3-amino-2-fluoropropil) fosfínico, así como al uso de dicha forma cristalina para el tratamiento de trastornos gastrointestinales, a composiciones farmacéuticas que la contienen, y a un procedimiento para la preparacion de la misma.
UY31558A 2007-12-21 2008-12-19 Nueva forma cristalina del acido (2r)-(3-amino-2-fluoropropil) fosfinico UY31558A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1576607P 2007-12-21 2007-12-21

Publications (1)

Publication Number Publication Date
UY31558A1 true UY31558A1 (es) 2009-08-03

Family

ID=40801457

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31558A UY31558A1 (es) 2007-12-21 2008-12-19 Nueva forma cristalina del acido (2r)-(3-amino-2-fluoropropil) fosfinico

Country Status (8)

Country Link
US (1) US20110034420A1 (es)
EP (1) EP2235027A4 (es)
AR (1) AR070045A1 (es)
CL (1) CL2008003841A1 (es)
PE (1) PE20091310A1 (es)
TW (1) TW200940559A (es)
UY (1) UY31558A1 (es)
WO (1) WO2009082345A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009082344A1 (en) * 2007-12-21 2009-07-02 Astrazeneca Ab Novel process for making (2r)-(3-amino-2-fluoropropyl)phosphinic acid form a

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904508D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
SE9904507D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
FR2810824B1 (fr) * 2000-06-26 2003-01-17 Cit Alcatel Dispositif de fixation pour appareil de telecommunication mobile
SE0102057D0 (sv) * 2001-06-08 2001-06-08 Astrazeneca Ab New Salts I
US20100317626A1 (en) * 2007-07-25 2010-12-16 Astrazeneca Ab The Use Of (3-Amino-2-Fluoropropyl) Phosphinic Acid For Treatment Of NERD
WO2009014490A1 (en) * 2007-07-25 2009-01-29 Astrazeneca Ab Combination of (3-amino-2-fluoropropyl)phosphinic acid and omeprazole for treating tlesr, gerd, and nerd
WO2009145716A1 (en) * 2008-05-28 2009-12-03 Astrazeneca Ab New pharmaceutical formulation useful in gerd therapy

Also Published As

Publication number Publication date
WO2009082345A1 (en) 2009-07-02
PE20091310A1 (es) 2009-09-30
CL2008003841A1 (es) 2010-04-16
US20110034420A1 (en) 2011-02-10
AR070045A1 (es) 2010-03-10
EP2235027A4 (en) 2011-06-22
TW200940559A (en) 2009-10-01
EP2235027A1 (en) 2010-10-06

Similar Documents

Publication Publication Date Title
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
UY33735A (es) Compuestos antivirales
DOP2014000012A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
CO6270342A2 (es) Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p)
PE20141155A1 (es) Analogos del acido epoxi-eicosatrienoico y metodos para hacer y de uso del mismo
ECSP13012494A (es) Inhibidores de oxadiazol de la producción de leucotrieno.
CR20120264A (es) Compuestos
CU20120099A7 (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
UY34917A (es) Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación
ECSP11011517A (es) Compuestos antivirales
ECSP11011348A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3
CR7876A (es) Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
UY32574A (es) Antagonistas del receptor cxcr3
EA200971140A1 (ru) Триарильные соединения и композиции, их содержащие
ECSP11011095A (es) Amidas del ácido 4-(1,2,3,4-tetrahidroisoquinolina-2-il)-4-oxobutírico sustituidas como moduladores de KCNQ2/3.
CO6470899A2 (es) 2,4-diaminopirimidinas para el tratamiento de enfermedades caracterizadas por proliferación celular excesiva o normal
ECSP11011346A (es) 3-Amino-2-mercaptoquinolina sustituida como modulador de KCNQ2/3
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
ECSP11011345A (es) 2-mercapto-3-aminopiridina sustituida como moduladores de kcnq2/3
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.
BR112014019289A8 (pt) Métodos para a preparação do composto de prome-dicamento de piperazina inibidor da ligação do hiv
IN2012DN01292A (es)
ECSP13012603A (es) Nueva formulacion del cetp(1)

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20121123